Cabometyx

Active Ingredient(s): Cabozantinib (S)-Malate
FDA Approved: * April 25, 2016
Pharm Company: * EXELIXIS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Cabometyx Overview

Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc. In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating ...

Read more Cabometyx Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cabozantinib

Recent Cabometyx Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cabozantinib (S)-Malate
  • Capsule: 20mg, 80mg
  • Tablet: 20mg, 40mg, 60mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Cabometyx: (3 results)

Sorted by National Drug Code
  • 42388-023 Cabometyx 60 mg Oral Tablet by Exelixis, Inc.
  • 42388-024 Cabometyx 20 mg Oral Tablet by Exelixis, Inc.
  • 42388-025 Cabometyx 40 mg Oral Tablet by Exelixis, Inc.

Other drugs which contain Cabozantinib (S)-Malate or a similar ingredient: (2 results)